Therapies such as pan-caspase inhibitors (Emricasan, VX-166), PPARδ agonists [78, 79], IL-22 [80], Serum amyloid P (SAP) [81], vascular adhesion protein 1 (VAP1) [82], lysophospholipids (LPA), and TGFβ inhibitors [83] all contributed to the amelioration of liver fibrosis by modulating fibroblast activation and ECM deposition. This evidence concerns the gene AOC3 and Hepatic fibrosis.